Clinical Trial Update: Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India

View source ↗

Summary

Post-marketing surveillance study updating the safety and usage of Ryzodeg (insulin degludec/insulin aspart) in diabetes patients in routine clinical practice i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ryzodeg (insulin degludec/insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED